UBS initiated coverage of Alvotech (ALVO) with a Buy rating and $18 price target Alvotech is a pure-play biosimilar company, with a ...

AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...

Just as Andrew Witty of UnitedHealth Group did in a call with investors last month, CVS Health’s CEO David Joyner defended ...

AbbVie's acquisition of Allergan significantly increased the firm's debt level. We expect the firm's net debt position to peak at close to $70 billion in 2020 but given the strong cash flows of AbbVie ...

The second part of our conversation with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and ...

According to Reuters, the grocery retailer notified Express Scripts in September 2022 of its plan to terminate the pharmacy ...

As biosimilar competition intensifies, Humira's market share is expected to ... provides easy-to-follow model portfolios designed for wealth accumulation. Curious if ABBV is one of these AI ...

CVS Health is seeing signs of stabilization in key business areas, prompting Leerink Partners to upgrade the stock from Market Perform to Outperform and raise its price target to $75 per share in a ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.